Sphingolipids in treatment and prevention of steatosis and...

Details Sphingolipids in treatment and prevention of steatosis and... Sphingolipids in treatment and prevention of steatosis and...

2011-03-15

2011-03-15

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S114000, C514S119000, C514S551000

Reexamination Certificate

active

07906488

ABSTRACT:
The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the prevention and/or treatment of elevated blood levels of cholesterol and triglycerides related to steatosis and hepatotoxic effects of medicaments and viral infections. In particular, the invention relates to the use of a sphingolipid such as phytosphingosine, sphingosine, sphinganine, ceramide, glycosylceramide and/or sphingomyelin, or a precursor or a derivative of a sphingolipid, or a pharmaceutically acceptable salt thereof, for the prevention and/or treatment of hepatotoxic effects such as hepatic steatosis, fibrosis and/or cirrhosis.

REFERENCES:
patent: 5190876 (1993-03-01), Kinkade, Jr. et al.
patent: 5232837 (1993-08-01), Merrill, Jr. et al.
patent: 5374616 (1994-12-01), Spiegel et al.
patent: 5478860 (1995-12-01), Wheeler et al.
patent: 5519007 (1996-05-01), Della Valle et al.
patent: 5830853 (1998-11-01), Baeckstroem et al.
patent: 6562606 (2003-05-01), Elias et al.
patent: 6610835 (2003-08-01), Liotta et al.
patent: 2001/0011076 (2001-08-01), Schwartz et al.
patent: 2002/0110587 (2002-08-01), Rodrigueza et al.
patent: 2002/0182250 (2002-12-01), Hori et al.
patent: 2003/0049286 (2003-03-01), Granger et al.
patent: 2003/0109044 (2003-06-01), Logan et al.
patent: 2004/0047851 (2004-03-01), Tabas et al.
patent: 2004/0063667 (2004-04-01), Kishikawa et al.
patent: 2004/0147615 (2004-07-01), Rinehart et al.
patent: 2004/0171557 (2004-09-01), Iian et al.
patent: 2007/0010483 (2007-01-01), Iian et al.
patent: 2007/0098808 (2007-05-01), Sampalis
patent: 196 02 108 (1997-07-01), None
patent: 0 373 038 (1990-06-01), None
patent: 0 988 860 (2000-03-01), None
patent: 1 291 340 (2003-03-01), None
patent: 1 452 181 (2004-09-01), None
patent: 2 492 259 (1982-04-01), None
patent: 2 820 037 (2002-08-01), None
patent: 61 152632 (1986-07-01), None
patent: 63 044842 (1998-02-01), None
patent: 11 269074 (1999-10-01), None
patent: 2000/350563 (2000-12-01), None
patent: 2001/158735 (2001-06-01), None
patent: 2001/158736 (2001-06-01), None
patent: 2001 213858 (2001-08-01), None
patent: 2002/068998 (2002-03-01), None
patent: 2002/226394 (2002-08-01), None
patent: 2003 137894 (2003-05-01), None
patent: 2001 008 569 (2001-02-01), None
patent: WO 92/03129 (1992-03-01), None
patent: WO 95/32002 (1995-11-01), None
patent: WO 97/11706 (1997-04-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 99/61581 (1999-12-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO 01/60807 (2001-08-01), None
patent: WO 01/72701 (2001-10-01), None
patent: WO 02/34062 (2002-05-01), None
patent: WO 02/102394 (2002-12-01), None
patent: WO 03/011873 (2003-02-01), None
patent: WO 03/088761 (2003-10-01), None
patent: WO 03/096983 (2003-11-01), None
patent: WO 2004/016257 (2004-02-01), None
patent: WO 2004/064819 (2004-08-01), None
patent: WO 2004/064820 (2004-08-01), None
patent: WO 2004/064823 (2004-08-01), None
patent: WO 2004/096140 (2004-11-01), None
Barenholz et al. (Biochemistry, vol. 7, No. 7, pp. 2603-2609; 1968).
Patani et al. (Chem Rev, vol. 96, No. 8, pp. 3147-3176; 1996).
Haller (Z Gesamte Inn Med, vol. 32, No. 8, pp. 124-128; 1977).
Stella (Expert Opinion on Therapeutic Patents, Prodrugs as therapeutics, vol. 14, No. 3, pp. 277-280; 2004).
Wolff (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977; 1994).
Testa (Biochemical Pharmacology, Prodrug Research: futile or fertile?, vol. 68, pp. 2097-2106; 2004).
Ettmayer et al. (Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, vol. 47, No. 10, pp. 2394-2404; 2004).
The Merck Manual ([online], www.merck.com [Retrieved on Jun. 20, 2009 from the Internet: <URL: http://www.merck.com/mmhe/sec10/ch136/ch136b.html?qt=hepatic%20steatosis&alt=sh]).
Auge, Nathalie et al.: “Sphingomyelin metabolites in vascular cell signaling and atherogensis” Progress in Lipid Research, vol. 39, No. 3, May 2000, pp. 207-229.
Beers, M.H. and R. Berkow: “The Merck Manual of Diagnosis and Therapy, seventeenth edition” 1999, Merck Research Laboratories, Whitehouse Station, N.J., XP002311213 p. 1655, col. 1, paragraph 4—p. 1656, col. 1, paragraph 3.
Beers, M.H. and R. Berkow: “The Merck Manual of Diagnosis and Therapy, seventeenth edition” 1999, Merck Research Laboratories, Whitehouse Station, N.J., XP002341450 p. 1062; tables 148-4.
Bibel, D. J. et al.: “Antimicrobial Activity of Sphingosines” Journal of Investigative Dermatology, vol. 98, No. 3, 1992, pp. 269-273.
Bischoff, A. et al..: “Sphingosine-1-Phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro” British Journal of Pharmacology, Basingstoke, Hants, GB, vol. 130, No. 8, Aug. 2000, pp. 1871-1877.
Chatterjee, Subroto: “Sphingolipids in atherosclerosis and vascular biology” Arteriosclerosis Thrombosis and Vascular Biology, vol. 18, No. 10, Oct. 1998, pp. 1523-1533.
Chong, P.H. et al.: “Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.” Pharmacotherapy, vol. 17(6), pp. 1157-1177; 1997.
Chung, N. et al.: “Phytosphingosine as a specific inhibitor of growth and nutrient import inSaccharomyces cerevisiae.” The Journal of Biological Chemistry. United States Sep. 21, 2001, vol. 276, No. 38, pp. 35614-35621.
Davaille et al. 2000. J. Biol. Chem., vol. 275, No. 44, pp. 34628-34633.
Fantini, J. et al.: “Synthetic Soluble Analogs of Galactosylceramide (GalCer) Bind to the V3 Domain of HIV-1 gp120 and Inhibit HIV-1-induced Fusion and Entry” Journal of Biological Chemistry, vol. 272, No. 11, 1997, pp. 7245-7252.
Howell et al. 2002. Current Organic Chemistry, vol. 6, No. 4, 2002, pp. 365-391.
Jiang, Xian-Cheng et al.: “Plasma sphingomyelin level as a risk factor for coronary artery disease” Arteriosclerosis Thrombosis and Vascular Biology, vol. 20, No. 12, Dec. 2000, pp. 2614-2618.
Jung et al. 1996. Journal of Natural Products, vol. 59, No. 3, pp. 319-322.
Kim, et al. 2000. Phytotherapy Res., 14(6), 448-451.
Leventhal, A. R. et al.: “Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux.” The Journal of Biological Chemistry. Nov. 30, 2001, vol. 276, No. 48, pp. 44976-44983.
Mei Jie et al.: “C2—Ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-I1 adipocytes.” Diabetes, vol. 51(3), pp. 631-637; 2002.
Merrill Jr., A. H. et al.: “Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases” Journal of Nutrition 1995 United States, vol. 125, No. 6 Suppl., pp. 1677S-1682S.
Ortenberg et al: Farmakologiya i Toksikologiya (Moscow), vol. 47, No. 4, 1984, pp. 102-105.
Rueda, R. et al.: “Addition of gangliosides to an adapted milk formula modifies levels of fecalEscherichia coliin preterm newborn infants” J. Pediatr., vol. 133, 1998, pp. 90-94.
Schmelz, E. M. et al.: “Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in cf1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis” Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 56, No. 21, Nov. 1, 1996, pp. 4936-4941.
Sosnowski et al. 1997. Journal of Urology, vol. 158, No. 1, pp. 269-274.
Sprong, R.C. et al.: “Bovine milk fat components inhibit food-borne pathogens.” International Dairy Journal, vol. 12, pp. 209-215, 2002.
Thurman et al. 1994. Transplant Int.: Off. J. Eur. Soc. For Organ Transplantation. 1994, vol. 7 suppl 1, pp. s167-s170.
Turinsky J et al: “Effect of sphingoid bases on basal and insulin-induced glucose uptake by skeletal muscle”, Journal of Cell Biology, vol. 115, No. 3 Part 2, 1991, p. 222A; & abstracts of papers presented at the thirty-first annual meeting of the american

Affiliated with

Also associated with

Rating

Sphingolipids in treatment and prevention of steatosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sphingolipids in treatment and prevention of steatosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sphingolipids in treatment and prevention of steatosis and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2756228